VYNE Therapeutics Inc.
VYNE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $142,673 | $23,936 | $8,602 | $52,491 |
| - Cash | $19,926 | $30,620 | $30,908 | $42,250 |
| + Debt | $99 | $214 | -$349 | $349 |
| Enterprise Value | $122,846 | -$6,470 | -$22,655 | $10,590 |
| Revenue | $501 | $424 | $477 | $931 |
| % Growth | 18.2% | -11.1% | -48.8% | – |
| Gross Profit | $501 | $424 | $477 | $931 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$43,633 | -$29,258 | -$34,223 | -$38,802 |
| % Margin | -8,709.2% | -6,900.5% | -7,174.6% | -4,167.8% |
| Net Income | -$39,834 | -$28,452 | -$23,210 | -$73,329 |
| % Margin | -7,950.9% | -6,710.4% | -4,865.8% | -7,876.4% |
| EPS Diluted | -0.94 | -2.77 | -10.65 | -25.65 |
| % Growth | 66.1% | 74% | 58.5% | – |
| Operating Cash Flow | -$33,972 | -$25,341 | -$29,200 | -$56,367 |
| Capital Expenditures | -$117 | $0 | $0 | $0 |
| Free Cash Flow | -$34,089 | -$25,341 | -$29,200 | -$56,367 |